Antibodies
22 January 2008
Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer18 January 2008
ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer16 January 2008
MorphoSys Discloses GM-CSF as Target of MOR103 Program16 January 2008
New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents15 January 2008
Progenics Initiates Phase 2 Clinical Trials for PRO 140, a Novel HIV Antibody Therapy15 January 2008
Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus8 January 2008
Medarex Announces Allowance of Investigational New Drug Application for Wholly Owned Fully Human Anti-CD70 Antibody, MDX-14118 January 2008
Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech4 January 2008
Genmab Announces HuMax-CD32B Pre-Clinical Program3 January 2008
Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against Rabies3 January 2008
Expanded Labeling for MabCampath(R) in Europe30 December 2007
MorphoSys Files Clinical Trial Application to Initiate First Phase 1 Clinical Study of its MOR103 Program22 December 2007
Elan and Wyeth Dose First Patient in North America in Phase 3 Program for Bapineuzumab (AAB-001) in Alzheimer’s Disease21 December 2007
Fresenius Biotech applies for the marketing authorization of the trifunctional antibody Removab (R) for the treatment of malignant ascites20 December 2007
Ablinx Extends Agreement With Wyeth20 December 2007
Abbott’s HUMIRA (R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis20 December 2007
Human Genome Sciences initiates second randomized Phase 2 trial of HGS- ETR 1 in combination with chemotherapy20 December 2007
R1507 antibody to enter Phase II study to treat sarcomaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports